| Daniel Leroy Waggoner, MD | |
|
23 Clara Dr, Suite 204, Mystic, CT 06355-1959 | |
| (860) 536-2995 | |
| (860) 572-0265 |
| Full Name | Daniel Leroy Waggoner |
|---|---|
| Gender | Male |
| Speciality | Allergy/immunology |
| Experience | 23 Years |
| Location | 23 Clara Dr, Mystic, Connecticut |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1558406066 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207K00000X | Allergy & Immunology | 045087 (Connecticut) | Primary |
| 207KA0200X | Allergy & Immunology - Allergy | 45087 (Connecticut) | Secondary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Shoreline Allergy And Asthma Associates Llp | 9739157819 | 3 |
News Archive
Since 1990, Creighton University School of Medicine professor and researcher Devendra K. Agrawal, Ph.D., has been awarded more than $20 million in research grants to study coronary artery heart disease. He is determined to eradicate the impact of this heart disease—the number one killer of men and women in the United States.
The commercial failure of Exubera- (Pfizer, New York, NY), the first inhaled insulin product to come to market, led other companies such as Eli Lilly-Alkermes to halt studies of similar drug delivery in development intended to compete for a share of the lucrative diabetes market. Does this signal defeat for efforts to deliver insulin via the lungs? The science and circumstances behind the Lilly-Alkermes decision to discontinue trials of the AIR- inhaled insulin product are explored in a special supplement to Diabetes Technology & Therapeutics, a peer-reviewed journal published by Mary Ann Liebert, Inc. (www.liebertpub.com). The supplement is available free online at www.liebertpub.com/dia
This post in the Center for Global Health Policy's "Science Speaks" blog examines a report by the PEPFAR Scientific Advisory Board (SAB) that offers six recommended treatment and prevention research priorities to U.S. Global AIDS Ambassador Eric Goosby and the Office of the Global AIDS Coordinator (OGAC) to guide future PEPFAR programs.
Rush University Medical Center is assessing whether minimally invasive surgery to relieve lower back pain differs from open surgery in terms of complication rate, recovery time, outcome and cost.
Cordis Corporation has entered into a distribution agreement with Ostial Solutions for the worldwide distribution of the OSTIAL PRO Stent Positioning System™. The OSTIAL PRO™ is the world's first and only aorto-ostial stent positioning system for coronary and peripheral applications. The OSTIAL PRO™ is intended to optimize the treatment of patients who require a stent implantation for treatment for aorto-ostial blockages.
› Verified 1 days ago
| Entity Name | Shoreline Allergy & Asthma Associates Llp |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1881757243 PECOS PAC ID: 9739157819 Enrollment ID: O20040917000539 |
News Archive
Since 1990, Creighton University School of Medicine professor and researcher Devendra K. Agrawal, Ph.D., has been awarded more than $20 million in research grants to study coronary artery heart disease. He is determined to eradicate the impact of this heart disease—the number one killer of men and women in the United States.
The commercial failure of Exubera- (Pfizer, New York, NY), the first inhaled insulin product to come to market, led other companies such as Eli Lilly-Alkermes to halt studies of similar drug delivery in development intended to compete for a share of the lucrative diabetes market. Does this signal defeat for efforts to deliver insulin via the lungs? The science and circumstances behind the Lilly-Alkermes decision to discontinue trials of the AIR- inhaled insulin product are explored in a special supplement to Diabetes Technology & Therapeutics, a peer-reviewed journal published by Mary Ann Liebert, Inc. (www.liebertpub.com). The supplement is available free online at www.liebertpub.com/dia
This post in the Center for Global Health Policy's "Science Speaks" blog examines a report by the PEPFAR Scientific Advisory Board (SAB) that offers six recommended treatment and prevention research priorities to U.S. Global AIDS Ambassador Eric Goosby and the Office of the Global AIDS Coordinator (OGAC) to guide future PEPFAR programs.
Rush University Medical Center is assessing whether minimally invasive surgery to relieve lower back pain differs from open surgery in terms of complication rate, recovery time, outcome and cost.
Cordis Corporation has entered into a distribution agreement with Ostial Solutions for the worldwide distribution of the OSTIAL PRO Stent Positioning System™. The OSTIAL PRO™ is the world's first and only aorto-ostial stent positioning system for coronary and peripheral applications. The OSTIAL PRO™ is intended to optimize the treatment of patients who require a stent implantation for treatment for aorto-ostial blockages.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Daniel Leroy Waggoner, MD 23 Clara Dr, Suite 204, Mystic, CT 06355-1959 Ph: (860) 536-2995 | Daniel Leroy Waggoner, MD 23 Clara Dr, Suite 204, Mystic, CT 06355-1959 Ph: (860) 536-2995 |
News Archive
Since 1990, Creighton University School of Medicine professor and researcher Devendra K. Agrawal, Ph.D., has been awarded more than $20 million in research grants to study coronary artery heart disease. He is determined to eradicate the impact of this heart disease—the number one killer of men and women in the United States.
The commercial failure of Exubera- (Pfizer, New York, NY), the first inhaled insulin product to come to market, led other companies such as Eli Lilly-Alkermes to halt studies of similar drug delivery in development intended to compete for a share of the lucrative diabetes market. Does this signal defeat for efforts to deliver insulin via the lungs? The science and circumstances behind the Lilly-Alkermes decision to discontinue trials of the AIR- inhaled insulin product are explored in a special supplement to Diabetes Technology & Therapeutics, a peer-reviewed journal published by Mary Ann Liebert, Inc. (www.liebertpub.com). The supplement is available free online at www.liebertpub.com/dia
This post in the Center for Global Health Policy's "Science Speaks" blog examines a report by the PEPFAR Scientific Advisory Board (SAB) that offers six recommended treatment and prevention research priorities to U.S. Global AIDS Ambassador Eric Goosby and the Office of the Global AIDS Coordinator (OGAC) to guide future PEPFAR programs.
Rush University Medical Center is assessing whether minimally invasive surgery to relieve lower back pain differs from open surgery in terms of complication rate, recovery time, outcome and cost.
Cordis Corporation has entered into a distribution agreement with Ostial Solutions for the worldwide distribution of the OSTIAL PRO Stent Positioning System™. The OSTIAL PRO™ is the world's first and only aorto-ostial stent positioning system for coronary and peripheral applications. The OSTIAL PRO™ is intended to optimize the treatment of patients who require a stent implantation for treatment for aorto-ostial blockages.
› Verified 1 days ago